Electrocardiographic Screening for Hypertrophic Cardiomyopathy and Long QT Syndrome: The Drivers of Cost-Effectiveness for the Prevention of Sudden Cardiac Death
- 634 Downloads
It is universally recognized that the prevention of sudden cardiac death (SCD) in youth is an important public health initiative. The best approach remains uncertain. Many European and Asian countries support the use of electrocardiograms (ECGs). In the United States, this is highly controversial. Many debate its cost-effectiveness. We designed a comprehensive economic model of two of the most prevalent causes of SCD identifiable by ECG, hypertrophic cardiomyopathy (HCM) and long QT syndrome (LQTS), to determine the drivers of uncertainty in the estimate of cost-effectiveness. We compared the cost-effectiveness of screening with history and physical examination (H&P) plus ECG to the current United States standard, H&P alone, for the detection and treatment of HCM and LQTS. We used a Markov model on a theoretical cohort of healthy 12-year-olds over a 70-year time horizon from a societal perspective, employing extensive univariable and probabilistic sensitivity analyses, to determine drivers of costs and effectiveness. The incremental cost-effectiveness of adding ECGs to H&Ps was $41,400/life-year saved. The model was highly sensitive to the effect of identification and treatment of previously undiagnosed individuals with HCM; however, it was insensitive to many variables commonly assumed to be significant, including the costs of ECGs, echocardiograms, and genetic testing, as well as the sensitivity and specificity of ECGs. No LQTS-related parameters were significant. This study suggests that the key to determining the cost-effectiveness of ECG screening in the United States lies in developing a better understanding of disease progression in the previously undiagnosed HCM population.
KeywordsCost-effectiveness ECG screening Sudden death Hypertrophic cardiomyopathy Long QT syndrome
Conflict of interest
- 1.Ackerman MJ, Priori SG, Willems S, Berul C, Brugada R, Calkins H et al (2011) HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies. This document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Heart Rhythm 8:1308–1339CrossRefPubMedGoogle Scholar
- 3.Centers for Medicare and Medicaid Services (2010) Available at: http://www.cms.gov/Medicare/Medicare.html. Accessed 15 June 2010
- 5.Corrado D, Pelliccia A, Bjornstad HH, Vanhees L, Biffi A, Borjesson M et al (2005) Cardiovascular pre-participation screening of young competitive athletes for prevention of sudden death: proposal for a common European protocol. Consensus statement of the Study Group of Sport Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology. Eur Heart J 26:516–524CrossRefPubMedGoogle Scholar
- 7.Costco (2010) Pharmacy drug information. Available at: http://www.costco.com/Pharmacy/DrugInformationaspx?p=1. Accessed 15 June 2010
- 11.Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS et al (2011) 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 58:e212–e260CrossRefPubMedGoogle Scholar
- 18.International Olympic Committee Medical Commission (2004) Sudden cardiovascular death in sports. Lousanne recommendations. Available at: http://www.olympic.org/Documents/Reports/EN/en_report_886.pdf.
- 27.Maron BJ, Thompson PD, Ackerman MJ, Balady G, Berger S, Cohen D et al (2007) Recommendations and considerations related to preparticipation screening for cardiovascular abnormalities in competitive athletes: 2007 update: a scientific statement from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: Endorsed by the American College of Cardiology Foundation. Circulation 115:1643–1655CrossRefPubMedGoogle Scholar
- 39.United States Census (2010) Available at: http://www.census.gov/population/age/. Accessed 2 Aug 2012